Last reviewed · How we verify
ω-3 polyunsaturated fatty acid
At a glance
| Generic name | ω-3 polyunsaturated fatty acid |
|---|---|
| Also known as | Omegaven®10% |
| Sponsor | Sir Run Run Shaw Hospital |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Effects of Fish Oil and Red Wine on Oxidative Stress Biomarkers (NA)
- Effects of Omega-3 Fatty Acids on Acute Graft-versus-Host Disease After Allogeneic Stem Cell Transplantation. (PHASE1, PHASE2)
- Effects of n3 LC PUFAs on Inflammatory, Immune and Senescence Features in Polyvascular Older Subjects (OMSAGE) (NA)
- Impact of Fish Oil Dose on Tissue Content and Function (NA)
- Effect of Supplementation With ω-3 Fatty Acids, Vitamin D and Calcium in Patients With Acute Lymphoblastic Leukemia. (NA)
- Supplementation With PUFA´s in Obese Children (NA)
- Modulation of Esophageal Inflammation in Barrett's Esophagus by Omega-3 Fatty Acids (PHASE4)
- Omega-3 and Vitamin D Supplements in Childhood T1D (PHASE2, PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- ω-3 polyunsaturated fatty acid CI brief — competitive landscape report
- ω-3 polyunsaturated fatty acid updates RSS · CI watch RSS
- Sir Run Run Shaw Hospital portfolio CI